Recent Price Movement and Market Context
On 23 Jan 2026, Bal Pharma’s stock closed near its 52-week low, underperforming its sector by 0.67% and registering a day change of -0.73%. The stock has experienced a consecutive two-day decline, resulting in a cumulative loss of 1.72% over this period. Notably, the share price is trading below all key moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day averages — signalling persistent bearish momentum.
In contrast, the broader market benchmark, the Sensex, opened flat and traded marginally lower by 0.08% at 82,237.53 points. The Sensex remains 4.77% below its 52-week high of 86,159.02, with its 50-day moving average positioned above the 200-day moving average, indicating a relatively more stable market environment compared to Bal Pharma’s share performance.
Long-Term Performance and Comparative Analysis
Over the past year, Bal Pharma’s stock has delivered a negative return of 39.15%, significantly lagging the Sensex’s positive 7.47% gain during the same period. The stock’s 52-week high was ₹128.74, underscoring the steep decline it has endured. Furthermore, the company’s performance has been below par not only in the last year but also over the last three years and three months, underperforming the BSE500 index consistently.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Metrics and Fundamental Assessment
Bal Pharma’s long-term fundamental strength remains weak, as reflected in its average Return on Capital Employed (ROCE) of 9.24%. This figure is below industry expectations and indicates limited efficiency in generating returns from capital investments. The company’s net sales have grown at a modest annual rate of 8.78% over the last five years, suggesting subdued top-line expansion relative to sector peers.
Debt servicing capacity is a notable concern, with a high Debt to EBITDA ratio of 4.53 times, indicating elevated leverage and potential strain on cash flows. The company has reported negative results for four consecutive quarters, with Profit Before Tax Less Other Income (PBT LESS OI) for the most recent quarter at a loss of ₹0.40 crore, representing a steep decline of 125.64% year-on-year.
Further highlighting financial stress, the half-year ROCE has dropped to 8.99%, while the operating profit to interest coverage ratio stands at a low 1.48 times, underscoring limited buffer to meet interest obligations from operating earnings.
Valuation and Peer Comparison
Despite the challenges, Bal Pharma’s valuation metrics present some relative attractiveness. The company’s ROCE of 7.8% corresponds with an enterprise value to capital employed ratio of 1.1, suggesting the stock is trading at a discount compared to its peers’ historical averages. This valuation gap reflects market caution but also indicates potential value recognition relative to sector benchmarks.
However, the stock’s profitability has declined by 11% over the past year, aligning with the negative share price performance. The majority ownership remains with promoters, maintaining concentrated control over corporate governance and strategic direction.
Holding Bal Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Market Sentiment and Rating Updates
Reflecting the company’s financial and operational performance, Bal Pharma’s Mojo Score stands at 14.0, with a Mojo Grade of Strong Sell as of 28 May 2025, upgraded from a previous Sell rating. The Market Cap Grade is rated at 4, indicating a relatively lower market capitalisation standing within its sector. These ratings encapsulate the cautious stance adopted by market analysts based on the company’s recent results and financial metrics.
Bal Pharma’s underperformance relative to the sector and broader market indices, combined with its valuation and financial ratios, continues to weigh on investor sentiment and share price levels.
Summary of Key Price and Performance Indicators
The stock’s proximity to its 52-week low of ₹67.15, combined with a 39.15% negative return over the last year, highlights the challenges faced by Bal Pharma Ltd. The share price remains significantly below its 52-week high of ₹128.74, underscoring the extent of the decline. The company’s financial indicators, including ROCE, debt ratios, and profitability trends, provide context for the current valuation and market positioning.
While the broader Sensex index has maintained relative stability, Bal Pharma’s stock continues to reflect sector-specific pressures and company-specific financial headwinds.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
